Amicus Therapeutics Inc. (FOLD)

NASDAQ: FOLD · Real-Time Price · USD

6.80

-0.88 (-11.46%)

At close: May 01, 2025, 12:11 PM

-11.46% (1D)

Bid	6.8
Market Cap	2.1B
Revenue (ttm)	528.29M
Net Income (ttm)	-56.11M
EPS (ttm)	-0.18
PE Ratio (ttm)	-37.81
Forward PE	23.26
Analyst	Buy

Ask	6.81
Volume	4,479,991
Avg. Volume (20D)	3,114,559
Open	6.61
Previous Close	7.68
Day's Range	6.63 - 7.07
52-Week Range	6.20 - 12.65
Beta	0.79

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzym...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 31, 2007

Employees 499

Stock Exchange NASDAQ

Ticker Symbol FOLD

Website https://amicusrx.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 149.82% from the latest price.

Stock Forecasts

Earnings Surprise

New

Amicus Therapeutics has released their quartely earnings on May 1, 2025:

Revenue of $125.2M misses estimates by $11.15M, with 13.40% YoY growth.

EPS of 0.03 misses estimates by -0.05, with 250.00% YoY growth.

Next Earnings Release

Amicus Therapeutics Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 hours ago New

Amicus Therapeutics shares are trading lower after... Unlock content with Pro Subscription

6 months ago

+14%

Amicus Therapeutics shares are trading higher after the company announced it entered into a license agreement with Teva and resolved its Galafold patent litigation.

News

Just now · zacks.com

Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.

1 week ago · zacks.com

Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · zacks.com

4 Healthcare Stocks to Buy as the Sector Faces Government Heat

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

3 weeks ago · zacks.com

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

4 weeks ago · zacks.com

New Strong Buy Stocks for April 1st

AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.

1 month ago · zacks.com

Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

1 month ago · seekingalpha.com

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)

Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving...

2 months ago · zacks.com

FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth

Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.

2 months ago · zacks.com

Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare wi...

2 months ago · businesswire.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's shareholders. Click here for additional...

Load More News